Teligent (NASDAQ: TLGT) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Teligent to similar companies based on the strength of its analyst recommendations, institutional ownership, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Teligent and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teligent 0 1 2 0 2.67
Teligent Competitors 944 3789 6007 164 2.49

Teligent presently has a consensus target price of $9.33, indicating a potential upside of 38.68%. As a group, “Pharmaceuticals” companies have a potential upside of 27.49%. Given Teligent’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Teligent is more favorable than its peers.

Volatility & Risk

Teligent has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Teligent’s peers have a beta of 0.86, indicating that their average share price is 14% less volatile than the S&P 500.

Institutional and Insider Ownership

66.0% of Teligent shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 22.6% of Teligent shares are held by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Teligent and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Teligent $72.39 million $6.48 million -42.06
Teligent Competitors $7.88 billion $2.51 billion 1.34

Teligent’s peers have higher revenue and earnings than Teligent. Teligent is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Teligent and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teligent -11.36% 1.49% 0.46%
Teligent Competitors -3,613.35% -52.29% -8.30%


Teligent beats its peers on 10 of the 13 factors compared.

Teligent Company Profile

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with's FREE daily email newsletter.